CLT030:靶向白血病干细胞的CLL1抗体药物偶联物用于治疗急性髓系白血病
急性髓系白血病(AML)标准治疗因难以清除对化疗耐药的白血病干细胞(LSC)而复发率高、生存率低。RNA测序证实CLL1在LSC高表达而正常造血干细胞及健康组织不表达,且在不同类型AML中表达一致。研究者开发了基于人源化抗CLL1抗体的位点特异性抗体药物偶联物CLT030,体外抑制LSC集落形成,在AML细胞肿瘤模型和患者来源异种移植模型中显示体内疗效,且对健康CD34+细胞分化的影响小于CD33-ADC。
要点
- CLL1在白血病干细胞高表达,正常造血干细胞及健康组织不表达。
- CLT030为位点特异性均一的CLL1抗体药物偶联物,在血液中稳定,内化后释放DNA结合载荷。
- CLT030体外抑制LSC集落形成,体内在AML细胞及患者来源异种移植模型中显示疗效。
核心结论
- CLL1-ADC(CLT030)可能是治疗AML的有效抗体药物偶联物疗法。
研究设计与样本
- 研究对分离的白血病干细胞进行RNA测序分析,并开发了基于人源化抗CLL1抗体的抗体药物偶联物CLT030,在体外集落形成实验、AML细胞肿瘤模型、AML患者来源异种移植模型及体内异种移植模型中评价。
主要发现
- RNA测序分析证实CLL1在分离的白血病干细胞上高表达,而在正常造血干细胞或其他健康器官组织中不表达。
- CLL1在不同类型AML中表达一致。
- CLT030在体外抑制白血病干细胞集落形成。
- CLT030在AML细胞肿瘤模型中显示稳健的体内疗效,在AML患者来源异种移植模型中显示肿瘤生长抑制。
- 在体外集落形成实验和体内异种移植模型中,CLL1-ADC对健康正常人CD34+细胞向各谱系分化的影响较CD33-ADC降低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The current standard of care for acute myeloid leukemia (AML) is largely ineffective with very high relapse rates and low survival rates, mostly due to the inability to eliminate a rare population of leukemic stem cells (LSCs) that initiate tumor growth and are resistant to standard chemotherapy. RNA-sequencing analysis on isolated LSCs confirmed C-type lectin domain family 12 member A (CLL1, also known as CLEC12A) to be highly expressed on LSCs but not on normal hematopoietic stem cells (HSCs) or other healthy organ tissues. Expression of CLL1 was consistent across different types of AML. We developed CLT030 (CLL1-ADC), an antibody-drug conjugate (ADC) based on a humanized anti-CLL1 antibody with 2 engineered cysteine residues linked covalently via a cleavable linker to a highly potent DNA-binding payload, thus resulting in a site-specific and homogenous ADC product. The ADC is designed to be stable in the bloodstream and to release its DNA-binding payload only after the ADC binds to CLL1-expressing tumor cells, is internalized, and the linker is cleaved in the lysosomal compartment. CLL1-ADC inhibits in vitro LSC colony formation and demonstrates robust in vivo efficacy in AML cell tumor models and tumor growth inhibition in the AML patient-derived xenograft model. CLL1-ADC demonstrated a reduced effect on differentiation of healthy normal human CD34+ cells to various lineages as observed in an in vitro colony formation assay and in an in vivo xenotransplantation model as compared with CD33-ADC. These results demonstrate that CLL1-ADC could be an effective ADC therapeutic for the treatment of AML.
引用
- Jiang YP, Liu BY, Zheng Q, et al. CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia. Blood Adv. 2018. PMID: 30037800. doi:10.1182/bloodadvances.2018020107
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。